中国神经再生研究(英文版) ›› 2022, Vol. 17 ›› Issue (2): 277-282.doi: 10.4103/1673-5374.317963

• 综述:脑损伤修复保护与再生 • 上一篇    下一篇

制定轻度新生儿脑病治疗策略面临的挑战

  

  • 出版日期:2022-02-15 发布日期:2021-10-08

Challenges in developing therapeutic strategies for mild neonatal encephalopathy

Alice McDouall, Guido Wassink, Laura Bennet, Alistair J. Gunn, Joanne O. Davidson*   

  1. Department of Physiology, The University of Auckland, Auckland, New Zealand
  • Online:2022-02-15 Published:2021-10-08
  • Contact: Joanne O. Davidson, PhD, joanne.davidson@auckland.ac.nz.
  • Supported by:
    This work was supported by The Health Research Council of New Zealand (18/225, 17/601, and 16/003).

摘要:

越来越多的证据表明,轻度新生儿脑病(NE)患儿的死亡、脑损伤和不良神经发育结局风险明显较高。对于中重度轻度新生儿脑病进行低温治疗时,治疗时间窗为出生后6小时内,而低温治疗前的回顾性影像学和脑电图评估要超过2-3天。这种诊断与治疗间的矛盾可能增加低温治疗轻度新生儿脑病出现脑损伤和神经系统不良结局的风险。轻度新生儿脑病患儿的不良短期结局包括癫痫发作、出院时神经系统检查异常、脑MRI异常和喂养困难。在患儿2-3岁时,轻度新生儿脑病与自闭症、语言和认知障碍的风险增加有关。由于这些患儿没有被纳入最初的治疗性低温随机对照试验中,因此尚无经批准的治疗策略。由于轻度新生儿脑病的损伤演变可能较慢,根据临床前的数据,需要专门为轻度新生儿脑病建立有效治疗的最佳治疗时间和治疗机会窗。急需开展治疗性低温治疗轻度新生儿脑病的随机对照试验,以确定治疗的安全性和有效性。文章综述了轻度新生儿脑病后不良结局的研究证据,并剖析制定轻度新生儿脑病治疗策略面临的一些挑战。

https://orcid.org/0000-0002-6781-4258 (Joanne O. Davidson) 

Abstract: There is increasing evidence that infants with mild neonatal encephalopathy (NE) have significant risks of mortality, brain injury and adverse neurodevelopmental outcomes. In the era of therapeutic hypothermia, infants need to be diagnosed within 6 hours of birth, corresponding with the window of opportunity for treatment of moderate to severe NE, compared to the retrospective grading over 2 to 3 days, typically with imaging and formal electroencephalographic assessment in the pre-hypothermia era. This shift in diagnosis may have increased the apparent prevalence of brain damage and poor neurological outcomes seen in infants with mild NE in the era of hypothermia. Abnormal short term outcomes observed in infants with mild NE include seizures, abnormal neurologic examination at discharge, abnormal brain magnetic resonance imaging and difficulty feeding. At 2 to 3 years of age, mild NE has been associated with an increased risk of autism, language and cognitive deficits. There are no approved treatment strategies for these infants as they were not included in the initial randomized controlled trials for therapeutic hypothermia. However, there is already therapeutic creep, with many centers treating infants with mild NE despite the limited evidence for its safety and efficacy. The optimal duration of treatment and therapeutic window of opportunity for effective treatment need to be specifically established for mild NE as the evolution of injury is likely to be slower, based on preclinical data. Randomized controlled trials of therapeutic hypothermia for infants with mild NE are urgently required to establish the safety and efficacy of treatment. This review will examine the evidence for adverse outcomes after mild NE and dissect some of the challenges in developing therapeutic strategies for mild NE, before analyzing the evidence for therapeutic hypothermia and other strategies for treatment of these infants.

Key words: asphyxia, electroencephalogram, erythropoietin, mild hypoxic ischemic encephalopathy, neonatal encephalopathy, neurological examination, neuroprotection, Sarnat score, therapeutic hypothermia